Clover, Dynavax COVID vaccine helps reduce household transmission of virus in trial

Nov. 30, 2022 6:13 AM ETDynavax Technologies Corporation (DVAX)By: Ravikash, SA News Editor8 Comments

Covid-19 Coronavirus Vaccine vials in a row macro close up

MarsBars/E+ via Getty Images

Clover Biopharmaceuticals reported additional data published in Clinical Infectious Diseases from a phase 2/3 trial of its vaccine SCB-2019 (CpG 1018/Alum) reducing the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

The company

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.